Results from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study were released at a session at the 9th South African AIDS Conference (SA AIDS 2019) in Durban, South Africa, on Thursday, June 13th. The session, which included presentations on the primary analysis, was recorded and can be viewed on YouTube here.
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study is an open-label randomised clinical trial comparing three highly effective, reversible methods of contraception — a progestogen-only injectable called depot-medroxyprogesterone acetate (DMPA), a levonorgestrel implant and the non-hormonal copper intrauterine device — to evaluate whether there is any difference in the risk of acquiring HIV infection among users of these methods.Read this fact sheet for more about the ECHO study.
The Southern African HIV Clinicians Society’s biannual conference, held in Johannesburg, South Africa, from 24-27 October 2018, focused on clinical content for HIV and TB health care workers in the region and featured a wide range of topics,
Despite the fact that people under the age of 18 make up about 25% of the global population, research among adolescents has been a neglected area. We know that it is important to conduct research among pediatric and adolescent populations, but to date the focus has remained on adults. Just how significant the risks are of not including adolescents in clinical trials emerged as a key theme at the 2nd International Workshop on HIV Adolescence, as well as the logistical, ethical, legal, justice, and human rights considerations that need to be taken into account when designing and implementing research involving adolescents.
As everyone in the field is aware, the NIH conducted an input process last year that concluded with a release of new HIV prevention research priorities that favor long acting, systemic formulations (like vaccines, implants and injectables) and negate the need for short acting, user-controlled, no
This photo story, about implementing the CHARISMA intervention pilot in Johannesburg, South Africa, illustrates how the pilot unfolded, starting with CHARISMA lay counselors conducting relationship assessments in 2016 with women using the vaginal dapivirine ring for HIV prevention in the MTN-025